Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 29, 2021 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Hold Corporate Update Monday, December 13th

HM43239 clinical update in AML after oral presentation at 2021 ASH Annual MeetingLuxeptinib clinical update in AML and B-cell cancers SAN DIEGO and TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Aptose...
November 22, 2021 16:02 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at the Piper Sandler 33rd Annual Healthcare Conference

SAN DIEGO and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
November 11, 2021 16:01 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the Third Quarter 2021

- Conference call and webcast at 5:00 pm ET today - - HM43239, myeloid kinome inhibitor with clinically validated activity added to pipeline - - HM43239 phase 1/2 study in AML advances to 200...
November 04, 2021 09:00 ET | Source: Aptose Biosciences, Inc.

Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting

SAN DIEGO and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
November 04, 2021 06:00 ET | Source: Aptose Biosciences, Inc.

Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome Inhibitor HM43239

HM43239 delivers multiple complete responses (CRs) in diverse R/R AML patients Aptose to host conference call and webcast today at 9:00 am ET SAN DIEGO and TORONTO and SEOUL, South Korea, Nov. 04,...
October 26, 2021 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021

SAN DIEGO and TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...
October 25, 2021 08:00 ET | Source: Aptose Biosciences, Inc.

Aptose Expands Senior Leadership Team

Janet Clennett, CPA, appointed Vice President, Finance Roger Davies, B.Sc., M. Phil, joins as Vice President, Operations SAN DIEGO and TORONTO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences...
August 30, 2021 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at September Investor Conferences

SAN DIEGO and TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
August 03, 2021 16:01 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the Second Quarter 2021

- Conference call and webcast at 5:00 pm EDT today - - Luxeptinib Phase 1a/b studies in AML and B cell malignancies fully enrolled at 750 mg dose - - APTO-253 Phase 1a/b study in AML / MDS treating...
July 20, 2021 16:01 ET | Source: Aptose Biosciences, Inc.

Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021

SAN DIEGO and TORONTO, July 20, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...